Navigation Links
IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Date:5/11/2010

EDMONTON, May 11 /PRNewswire/ - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration (FDA) to market its lead product, Occlusin(R) 500 Artificial Embolization Device (OCL 500) in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours. IMBio filed the 510(k) submission in December 2009. OCL 500 is the first biodegradable embolization device cleared for marketing by the FDA.

OCL 500 is a patented, first in class embolization agent that represents a paradigm shift in treatment compared to currently marketed embolic agents. OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 microspheres rapidly form a tight, efficient, site-specific and platelet-rich clot that cuts off the blood supply to tumours. The OCL 500 microspheres then completely biodegrade over time, allowing the treated blood vessels to re-open and restore normal blood flow. This is important because it enables multiple embolization treatments of unresectable hypervascularized tumours, such as those associated with liver and kidney cancer, through the same vascular pathway.

Mike Stewart, CEO of IMBio, stated, "No other embolization agent on the market today offers the advantages that OCL 500 microspheres offer. We believe that OCL 500 has the potential to broadly expand the number of embolization treatments conducted each year, and we are delighted to bring this very exciting product to
'/>"/>

SOURCE IMBiotechnologies Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
3. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
4. LS9's UltraClean Diesel™ Receives EPA Registration
5. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Indiana Collaborative Receives $10.3 Million in Federal Stimulus Funds to Improve Healthcare through Information Technology
8. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
9. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
10. Gems Sensors & Controls Receives ISO-13485:2003 Certification
11. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... New interactive learning forums ... leaders of the medical device industry at the ... expo, from June 18-20 in Philadelphia ... ) , These all-new MedTech ... practical presentations and implementable solutions on the most ...
(Date:5/17/2013)... 2013  Yongye International, Inc. (NASDAQ: YONG ... and distributor of crop nutrient products in ... that, on May 16, 2013, the special committee (the ... of Directors") was provided a letter (the "Letter") issued ... ) Limited ("Abax") to Full Alliance International Limited ("Full ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... VANCOUVER, June 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced the completion ... lung biopsy track plug., "Our proprietary Bio-Seal ... used to diagnose lung cancer," said Dr.,William Hunter, ...
... ANGELES, June 3 Signalife, Inc. (Amex:,SGN) has ... Ehrlichman -- who is,already a member of the ... Operating Officer. In that capacity, Mr. Ehrlichman,s primary ... will be on,sales and marketing of the company,s ...
... MATEO, Calif., June 3 NeurogesX, Inc.,(Nasdaq: ... and,commercializing novel pain management therapies, announced that it,submitted ... U.S. Food,and Drug Administration for the clinical development ... liquid,formulation of capsaicin. The Company further announced that ...
Cached Biology Technology:Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4Signalife Appoints Lee Ehrlichman President and Chief Operating Officer 2Signalife Appoints Lee Ehrlichman President and Chief Operating Officer 3NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998 2NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998 3
(Date:5/16/2013)... Illustrating a commitment to the support of ... (AGA) Research Foundation has announced the inaugural AGA ... recipients. Supported by the National Institute of Diabetes ... award helps underrepresented minority students to further their ... , "By establishing this new award, AGA demonstrates ...
(Date:5/16/2013)... adults living closer to a fast food restaurant had ... lived further away from fast food, according to researchers ... and this association was particularly strong among those with ... online in the American Journal of Public Health ... a fast food restaurant, and among lower-income African-Americans, the ...
(Date:5/16/2013)... CAMBRIDGE, MA -- Injectable nanoparticles developed at MIT ... Type 1 diabetes to constantly monitor their blood-sugar ... nanoparticles were designed to sense glucose levels in ... amount of insulin, thereby replacing the function of ... with Type 1 diabetes. Ultimately, this type of ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... of the University of Illinois at Urbana-Champaign first documented ... three colleagues report they've solved the ensuing, long-running mystery ... survive in icy waters, are produced. , "Ever since ... they had to be produced in the liver, since ...
... a laboratory version of boot camp may help patients ... researchers. In essence, that's the concept behind the development ... own souped up dendritic cells, which have been galvanized ... fighting the virus unique to that individual. , At ...
... sphere penetrates deeply into ovarian cancer tumor cells, stifling ... tumors, researchers at The University of Texas M. D. ... of Clinical Cancer Research. , The mouse model experiment, ... potent delivery system for short interfering RNA (siRNA) to ...
Cached Biology News:Researchers discover which organs in Antarctic fish produce antifreeze 2Researchers discover which organs in Antarctic fish produce antifreeze 3T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 2Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 3
... The standard electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... Detergent-OUT SDS Kit is a simple high ... solutions. Removes detergents without significant dilution ... protein solution on the Detergent-OUT Spin column ... Med columns are suitable for removing detergent ...
... tissue microarrays are derived from frozen embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... tissue microarrays are derived from frozen embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
Biology Products: